Collegium Pharmaceutical, Inc
A pharmaceutical company making medicines for pain and ADHD, including the opioid painkiller Xtampza ER (built on its DETERx abuse-deterrent technology), Belbuca, the Nucynta products, and Jornay PM, an evening-dosed ADHD stimulant. Founded in 2002 by Michael Heffernan to develop safer opioids, its name comes from the Latin "collegium," meaning a band of colleagues working together. The company even named its technology DETERx — a nod to deterring misuse, which is why its microsphere-in-capsule pain pills are hard to crush or inject.
Granted 17.4K · Sold 4.1K
Granted 17.4K
Sold 20.2K
Sold 50.0K
Granted 17.4K · Sold 8.7K
Granted 8.7K
Granted 8.7K
Granted 8.7K · Sold 4.5K
Granted 17.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Freund John GordonDirector · 4 transactions | +7.3% | 195.0K | 17.4K | — | 4.1K |
| Santini GinoDirector · 2 transactions | +18.4% | 112.5K | 17.4K | — | — |
| Dieter DavidEVP & General Counsel · 3 transactions | -20.8% | 77.1K | — | — | 20.2K |
| Dreyer ScottEVP & Chief Commercial Officer · 2 transactions | -38.6% | 75.3K | — | — | 50.0K |
| Bohlin Garen GDirector · 3 transactions | +14% | 71.0K | 17.4K | — | 8.7K |
| Balice-Gordon Rita J.Director · 1 transaction | +16.6% | 61.4K | 8.7K | — | — |
| Paya Carlos VDirector · 1 transaction | +44.6% | 28.3K | 8.7K | — | — |
| Lurker NancyDirector · 2 transactions | +18.8% | 26.8K | 8.7K | — | 4.5K |
| Glancy Donovan MichaelDirector · 1 transaction | — | 17.5K | 17.5K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: -87.5K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.